33 results on '"Philippe Kestemont"'
Search Results
2. Botulinum toxin type A for the treatment of excessive gingival display – A systematic review
- Author
-
Simon Rasteau, Charles Savoldelli, Cécile Winter, Barbara Lerhe, Laurent Castillo, and Philippe Kestemont
- Subjects
Otorhinolaryngology ,Gingiva ,Humans ,Facial Muscles ,Surgery ,Botulinum Toxins, Type A ,Esthetics, Dental ,Oral Surgery ,Smiling - Abstract
Gummy smile has traditionally been treated with invasive or demanding surgical and orthodontic techniques. Several studies have shown that targeted injection of the upper lip elevator muscles with botulinum toxin is an effective treatment for this condition. However, no standardized injection protocol with reproducible results has yet been published. A systematic review of the literature has been performed using Medline, Scopus, and Embase. All articles relevant to the research question were analyzed. After removing duplicates, 162 articles were selected, of which 9 were included in the analysis after applying exclusion and inclusion criteria, for a total of 269 patients. Onabotulinum toxin type A (ONA-BoNTA) was used in 7 studies and abobotulinum toxin type A (ABO- BoNTA) in 2 studies, at various dilutions. The number of sites injected varied from 1 to 3 per side, with variable targeting of the Levator labii superioris alaeque nasalis, Levator labii superioris, Zygomaticus minor, Zygomaticus major and Orbicularis oris. The dose used per side varied from 1.25 to 6 U of ONA-BoNTA and from 2.5 to 7.5 U of ABO- BoNTA. The injection protocol was tailored to the type of gingival smile in one study only, another study compared results of targeting two different muscles, and one study evaluated different dosages of toxin for the same injection site. The average improvement ranged from 24.85% to 99.65% and the effect persisted from 12 to 36 weeks. Very good patient satisfaction was reported in 6 studies. Fourteen adverse events were reported, all of them mild and transient. The treatment of gummy smile by botulinum toxin injection is effective, safe, rapid, minimally invasive and reversible. Protocols vary widely in the literature and no standardized procedure emerges. A patient-specific approach, adapted to their anatomy, type of gummy smile and the severity of the exposure seems to be the most appropriate. Randomized controlled studies are needed to make this approach more systematic.
- Published
- 2022
3. Long‐term efficacy and safety of a hyaluronic acid dermal filler based on <scp>Tri‐Hyal</scp> technology on restoration of midface volume
- Author
-
Philippe Kestemont, Ferial Fanian, Philippe Garcia, Anne Grand‐Vincent, Laurent Benadiba, Henry Delmar, Isaac Bodokh, Patrick Brun, Frédéric Braccini, Christophe Desouches, Jérôme Paris, Karim Nadra, Catherine Salomon, and Patrick Trevidic
- Subjects
Dermatology - Published
- 2023
4. Comparative clinical study for the efficacy and safety of two different hyaluronic acid‐based fillers with <scp>Tri‐Hyal</scp> versus Vycross technology: A long‐term prospective randomized clinical trial
- Author
-
Frederic Braccini, Ferial Fanian, Philippe Garcia, Henry Delmar, Federico Loreto, Laurent Benadiba, Karim Nadra, and Philippe Kestemont
- Subjects
Dermatology - Abstract
Hyaluronic acid-based fillers have an immediate volumizing effect for the treatment of dermal contour deformities and to smooth dermal depressions formed by the loss of volume. A previous study on 2016-2018 has shown the efficacy and safety of the HA-based filler ART FILLER® Volume on the midface only, but not in a comparative manner.In this context, an 18 months prospective randomized single-blind study of the non-inferiority of ART FILLER® Volume versus the reference product Juvéderm Voluma® was performed on the midface, temple, and jawline, and non-comparative study on the chin. The efficacy and the longevity were evaluated for the selected face areas via dedicated clinical scoring systems after a single filler injection without any re-touch or re-injection. The short- and long-term adverse effects were also recorded.The observations confirmed the non-inferiority of ART FILLER® Volume versus the reference product on the different injected areas. For both fillers, the beneficial effects on volumes restoration were maintained 18 months post-injection; however, these effects were diminished among the time. Furthermore, injections of Art Filler® Volume were well tolerated by the subjects and showed less acute side effects compared with the reference product that may be explained by a lower induction of inflammation.
- Published
- 2022
5. Liquid Spreader Grafts: Internal Nasal Valve Opening with Hyaluronic Acid
- Author
-
Thomas Radulesco, Cécile Winter, Philippe Kestemont, Frédéric Braccini, Laurent Castillo, and Justin Michel
- Subjects
Surgery - Abstract
Nasal valve disorders frequently give rise to nasal obstruction. Dermal fillers could be used in the internal valve area to generate valve widening. The goal of this study was to report our "liquid spreader" procedure consisting in the injection of hyaluronic acid (HA) at the internal nasal valve in patients complaining of nasal obstruction.The procedure described in this paper is suitable for patients with unilateral or bilateral nasal obstruction related to architectural features resulting in narrowing of the internal nasal valve. HA is injected along the internal valve from a single entry point located at the anterior part of the internal valve, thus creating a volume which will induce nasal valve widening. Rhinomanometries and visual analog scales (VAS) regarding nasal obstruction were collected before and after the procedure.Sixteen patients were enrolled (7 females). Mean age was 44 years (min=24 y-o, max=65 y-o). Thirteen presented nasal valve narrowing without septal deviation while 3 patients had high septal deviation. Before injection, mean nasal resistances were 3.4±5.6 sPa/mL (min=0.55, max=19.8). One month after injection, mean nasal resistances were 0.38±0.26 sPa/mL (min = 0.20, max = 0.85). The difference was statistically significant (p=0.049). VAS scores were improved with a trend back to baseline after 12 months.The liquid spreader is a useful procedure that can be combined with non-surgical esthetic rhinoplasties. Level of Evidence IV This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
- Published
- 2022
6. Liquid AbobotulinumtoxinA: Pooled Data From Two Double-Blind, Randomized, Placebo-Controlled Phase III Studies of Glabellar Line Treatment
- Author
-
Said Hilton, Philippe Kestemont, Gerhard Sattler, Magali Volteau, Catherine Thompson, Bill Andriopoulos, Inna Prygova, Anna-Karin Berg, and Benjamin Ascher
- Subjects
Treatment Outcome ,Double-Blind Method ,Neuromuscular Agents ,Clinical Trials, Phase III as Topic ,Humans ,Reproducibility of Results ,Surgery ,Dermatology ,General Medicine ,Forehead ,Botulinum Toxins, Type A ,Skin Aging ,Randomized Controlled Trials as Topic - Abstract
AbobotulinumtoxinA (aboBoNT-A) solution is a new ready-to-use formulation developed to reduce preparation time and improve reproducibility of injections.To further evaluate treatment of moderate-to-severe glabellar lines (GLs) using pooled data from 2 Phase III studies.Following double-blind treatment with 50 U aboBoNT-A solution (n = 251) or placebo (n = 123), GL severity was assessed by investigators (ILA) and subjects (SSA). Other assessments included subject-reported time to onset, subject satisfaction, FACE-Q, and adverse events.One month after aboBoNT-A solution treatment, 88% had none-or-mild GLs at maximum frown and 93% had ≥1-grade improvement in ILA (similar for SSA), 24% to 27% remaining improved at Month 6. Glabellar lines responder rates remained higher than placebo throughout Month 6 ( p.001). Almost two-thirds of subjects reported onset within 3 days, nearly a quarter reporting effect by Day 1. Subject satisfaction with GL appearance, and FACE-Q satisfaction with facial appearance overall and psychological well-being were also improved over placebo throughout Month 6, p.05. Treatment-related adverse events were nonserious and mild or moderate.Pooled analysis confirmed a duration of effect on GLs of up to 6 months for aboBoNT-A solution, with onset starting within 24 hours, high subject satisfaction, and improved psychological well-being. The treatment was well tolerated.
- Published
- 2022
7. A Safe Nonsurgical Rhinoplasty Procedure
- Author
-
Thomas Radulesco, Frédéric Braccini, Philippe Kestemont, Cécile Winter, Laurent Castillo, and Justin Michel
- Subjects
Cannula ,Humans ,Surgery ,Hyaluronic Acid ,Nose ,Rhinoplasty ,Injections - Abstract
Nonsurgical rhinoplasty procedures are not without risks: although rare, intravascular injections of hyaluronic acid can lead to serious complications. Very few authors have reported using cannulas for filler injection in the nose. The purpose of this article is to describe how the authors perform nonsurgical rhinoplasty using a single entry point and cannulas, significantly reducing vascular and infection risks. The procedure described in this article can be applied to all indications of nonsurgical rhinoplasty. The key point of the authors' procedure is the definition of a single, medial entry point. Using a 5-cm, 25-gauge, dome-shaped cannula, all nasal regions can be reached, from the anterior nasal spine to the nasion. The authors' nonsurgical rhinoplasty procedure using cannulas reduces complications and provides results similar to those achieved with needles.
- Published
- 2022
8. Repeated Full-Face Aesthetic Combination Treatment With AbobotulinumtoxinA, Hyaluronic Acid Filler, and Skin-Boosting Hyaluronic Acid After Monotherapy With AbobotulinumtoxinA or Hyaluronic Acid Filler
- Author
-
Hugues Cartier, Per Bergentz, Maria Norberg, Carolina Edwartz, Per Hedén, Cecilia Skoglund, Henry Delmar, and Philippe Kestemont
- Subjects
Adult ,Male ,Esthetics ,Acetylcholine Release Inhibitors ,Dentistry ,Cosmetic Techniques ,Dermatology ,law.invention ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Combined treatment ,Patient satisfaction ,Randomized controlled trial ,law ,Dermal Fillers ,ABO blood group system ,Hyaluronic acid ,Humans ,Rejuvenation ,Medicine ,Botulinum Toxins, Type A ,Hyaluronic Acid ,Adverse effect ,Wrinkle ,business.industry ,General Medicine ,Middle Aged ,Glabella ,Combined Modality Therapy ,Skin Aging ,Treatment Outcome ,medicine.anatomical_structure ,chemistry ,Patient Satisfaction ,Face ,030220 oncology & carcinogenesis ,Retreatment ,Female ,Original Article ,Surgery ,medicine.symptom ,business - Abstract
Background Full-face aesthetic treatment involving several treatment modalities may improve facial aesthetic outcome. Objective To evaluate clinical outcomes and patient perceptions of monotherapy with either abobotulinumtoxinA (ABO) or hyaluronic acid (HA) filler followed by full-face combination treatments of ABO, HA filler, and skin-boosting HA (RSB). Materials and methods Subjects aged 35 to 50 years were randomized to monotherapy with 50 s.U ABO in the glabella or ≤1 mL HA filler in the nasolabial folds (NLFs)/cheeks. At Month 6 and Month 12, all subjects received combination treatment with ≤50 s.U ABO in the glabella, ≤2 mL HA filler in the NLFs/cheeks (and other facial areas as applicable), and ≤1 mL RSB (additional RSB treatment at Month 7). Assessments included global facial aesthetic appearance and improvement, first impression, perceived age, wrinkle severity, satisfaction questionnaires, and adverse events. Results Repeated full-face combination treatment with ABO, HA filler, and RSB was associated with considerably higher levels of aesthetic improvement and subject satisfaction than monotherapy with ABO or HA filler. Improvement rate of glabellar lines was increasing with each treatment. Conclusion Repeated combination treatment achieved greater change in global facial aesthetic appearance than monotherapy. Aesthetic improvement and subject satisfaction was high and increased with each treatment. All treatments were well tolerated.
- Published
- 2020
9. Significantly Increased Patient Satisfaction Following Liquid Formulation AbobotulinumtoxinA Treatment in Glabellar Lines: FACE-Q Outcomes From a Phase 3 Clinical Trial
- Author
-
Martina Kerscher, Philippe Kestemont, Philippe Picaut, Philippe Le Berre, Isaac Bodokh, Said Hilton, Benjamin Ascher, Berthold Rzany, Magali Volteau, Dominique Boineau, Ernst Magnus Noah, and Marc Heckmann
- Subjects
medicine.medical_specialty ,Phases of clinical research ,030230 surgery ,Placebo ,law.invention ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Randomized controlled trial ,law ,medicine ,In patient ,AcademicSubjects/MED00987 ,business.industry ,Asj/1 ,Original Articles ,General Medicine ,Body Contouring ,Clinical Practice ,Clinical trial ,Editor's Choice ,Standard error ,Physical therapy ,Surgery ,business - Abstract
Background The FACE-Q patient-reported outcome assesses patient experiences/outcomes with aesthetic facial procedure. A recent trial of abobotulinumtoxinA (ASI, liquid formulation) was the first to our knowledge to assess satisfaction with FACE-Q after glabellar line (GL) injection. Objectives The authors sought to evaluate patient satisfaction with ASI for GL treatment employing 3 FACE-Q scales: facial appearance, psychological well-being, and aging appearance. Methods This was a Phase 3, randomized, double-blind, placebo-controlled trial (NCT02353871) of ASI 50 units in adults with moderate-to-severe GL with 6-month follow-up. Results Significantly greater least squares mean changes from baseline were associated with ASI treatment (N = 125) vs placebo (N = 59) for satisfaction with facial appearance at all visits until day 148 (5 months; P < 0.0001-0.0037), psychological well-being at all visits (P < 0.0001-0.0279), and aging appearance at all visits except day 148 (P < 0.0001-0.0409). Significant differences (ASI vs placebo) were observed at all visits for individual items: “how rested your face looks” (P < 0.0001-0.0415), “I feel okay about myself” (P = 0.0011-0.0399), and “I feel attractive” (P < 0.0001-0.0102). Maximal least squares mean (standard error) changes in aging appearance score were −1.4 (0.3; ASI) and −0.3 (0.4; placebo). Investigators’ live assessment of GL at maximum frown significantly correlated with improvements in FACE-Q facial appearance and psychological scales (all patients: r = −0.41 and r = −0.36 [both P < 0.0001], respectively). Conclusions Significant improvements in patient satisfaction with aging, facial appearance, and, importantly, psychological well-being were demonstrated with ASI employing FACE-Q scales up to 5 to 6 months post-injection. Results support a long duration of efficacy with ASI and use of FACE-Q in future trials and clinical practice. Level of Evidence: 1
- Published
- 2019
10. Liquid Formulation of AbobotulinumtoxinA: A 6-Month, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of a Single Treatment, Ready-to-Use Toxin for Moderate-to-Severe Glabellar Lines
- Author
-
Philippe Picaut, Said Hilton, Philippe Le Berre, Philippe Kestemont, Martina Kerscher, Marc Heckmann, Dominique Boineau, Benjamin Ascher, Ernst Magnus Noah, Berthold Rzany, Isaac Bodokh, and Magali Volteau
- Subjects
Moderate to severe ,business.industry ,Surrogate endpoint ,Placebo-controlled study ,General Medicine ,030230 surgery ,Placebo ,Double blind ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Patient satisfaction ,Anesthesia ,Clinical endpoint ,Medicine ,Ready to use ,Surgery ,business - Abstract
Background Safety and efficacy of botulinum toxin A for glabellar line (GL) treatment are well established. Currently approved formulations require reconstitution before injection. Objectives The authors sought to assess 6-month efficacy, safety, and patient satisfaction of new ready-to-use abobotulinumtoxinA solution for injection (ASI) in patients with moderate-to-severe GL at maximum frown. Methods The authors conducted a phase 3, double-blind, randomized, placebo-controlled trial (NCT02353871). Patients (N = 185) were randomized (2:1) to receive ASI 50 U or placebo. GL severity was evaluated at days 8, 15, 29, 57, 85, 113, 148, and 183 employing a 4-point scale for investigator’s live assessment (ILA) and subject's self-assessment (SSA). Primary endpoint was ILA of GL at maximum frown at day 29, and secondary endpoints were ILA and SSA of GL at maximum frown (all time points), patient satisfaction with GL appearance, time to onset, and duration of action. Results Responder rates were significantly higher for ASI vs placebo (88.3% vs 1.4%; P < 0.0001) at day 29 by ILA and all time points by ILA (P < 0.0001-0.0441) and SSA (P < 0.0001-0.0036). Sixty percent of patients reported onset of treatment response on or before day 3 (P < 0.0001 vs placebo), and in 5% of patients, efficacy by ILA lasted 6 months (day 183; P = 0.0441 vs placebo). Patient satisfaction rates were significantly higher for ASI vs placebo at all visits (P < 0.0001). Safety was comparable with the known abobotulinumtoxinA profile. Conclusions ASI was significantly efficacious for improving moderate or severe GL vs placebo by investigator and patient assessment. ASI was associated with high patient satisfaction, a long duration of action, and comparable safety profile to abobotulinumtoxinA. Level of Evidence: 1
- Published
- 2019
11. European Multicenter Prospective Study Evaluating Long-Term Safety and Efficacy of the Polycaprolactone-Based Dermal Filler in Nasolabial Fold Correction
- Author
-
Philippe Kestemont, Patrick Brun, Henry Delmar, Marie-Odile Christen, Marion Moers-Carpi, and Isaac Bodokh
- Subjects
Adult ,Male ,medicine.medical_specialty ,Nasolabial Fold ,Time Factors ,Polyesters ,Cosmetic Techniques ,Dermatology ,Dermal Fillers ,Young Adult ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Rating scale ,medicine ,Clinical endpoint ,Humans ,Prospective Studies ,Adverse effect ,Prospective cohort study ,Wrinkle ,Aged ,business.industry ,General Medicine ,Middle Aged ,Nasolabial fold ,Surgery ,Europe ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,Long term safety ,medicine.symptom ,business - Abstract
Background Age-related changes affecting facial areas can be corrected using minimally invasive dermal fillers. The use of polycaprolactone-dermal filler (PCL-filler) in aesthetics is increasing. Objective To evaluate the long-term safety and efficacy of the PCL-filler, in a European, multicenter, prospective study. Materials and methods Subjects (n = 90) with moderate/severe nasolabial folds (Wrinkle Severity Rating Scale [WSRS]: 3 to 4) were treated on Day 0 with a single injection of similar volume on each side; safety and efficacy assessments were performed over an 18-month period. In 1 of the 3 study centers, safety was evaluated at 30 months. Results At Month 12 (M12; primary endpoint), 84% of subjects showed a ≥1-point improvement on the WSRS (M6: 92%; M18: 64%). From the investigator/subject's evaluation, from Day 7 to M12, Global Aesthetic Improvement was reported for >90% of subjects, with the effect maintained for up to 18 months in >80% of patients. Subjects/investigators reported high satisfaction and skin quality improvement. Most of the immediate injection-site reactions disappeared after 2 to 4 days. No severe or unexpected adverse events were reported. Conclusion This study demonstrated the long-term safety and efficacy of the PCL-filler, with safety confirmed for up to 30 months.
- Published
- 2021
12. A hyaluronic acid-based filler reduces lipolysis in human mature adipocytes and maintains adherence and lipid accumulation of long-term differentiated human preadipocytes
- Author
-
Karim Nadra, Philippe Kestemont, Hugues Cartier, Ferial Fanian, Mayoura Keophiphath, Mathilde André, Frederic Braccini, and Emmanuelle Marchaud
- Subjects
medicine.medical_specialty ,Lipolysis ,adipocytes ,Adipose tissue ,Special Issue: Injectables Articles ,Human skin ,Dermatology ,Cosmetic Techniques ,Extracellular matrix ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Dermis ,Internal medicine ,Dermal Fillers ,hypodermis ,Hyaluronic acid ,hyaluronic acid ,medicine ,Humans ,Original Contribution ,Lipids ,Skin Aging ,Endocrinology ,medicine.anatomical_structure ,chemistry ,Adipogenesis ,Cell culture ,030220 oncology & carcinogenesis - Abstract
The beneficial role of subcutaneous adipose tissue in skin rejuvenation derived from its capacity to fill the under‐layer volumes but also from its ability to regulate the extracellular matrix production by dermis fibroblasts. Hyaluronic acid (HA), a major component of the extracellular matrix, is a commonly used injectable dermal filler showing excellent efficiencies to maintain tissue augmentation even after its biodegradation. To improve their stability, the HA molecules can also be “cross‐linked” to each other. The effects of cross‐linked HA‐based fillers on the dermal structure are well known. For safety reasons, most of the physicians prefer to use the blunt cannula for injections. However, evidences showed that the cannula could not be located in the dermis, but it passes through immediate hypodermis and the long‐lasting effect of cross‐linked HA‐based fillers may be related to its effects on adipose tissue. To test whether cross‐linked HA has a direct effect on human adipocytes, we treated isolated adipocytes and precursors cells from human skin donors with cross‐linked HA. Biochemical and cellular analysis demonstrated that treatment by cross‐linked HA showed beneficial effects on differentiated cell adherence and survival as well as reduced basal and induced lipolysis in fully mature adipocytes. Taken together, these data showed that cross‐linked HA promoted cell adherence and preserved the adipogenic capacity of preadipocytes during prolonged cell culture, bringing additional evidences of the beneficial role of cross‐linked HA‐based fillers in maintenance of the subcutaneous fat mass. This first study could defend a preventive approach to facial volume loss during natural aging.
- Published
- 2020
13. Perioral Region
- Author
-
Krishan Mohan Kapoor, Philippe Kestemont, Jay Galvez, André Braz, John J. Martin, and Dario Bertossi
- Published
- 2020
14. IncobotulinumtoxinA Is an Effective and Well-Tolerated Treatment for Upper Facial Lines: Results From an Open-Label Extension Period of a Phase III Study
- Author
-
Barbara Ellers-Lenz, Ernst Magnus Noah, Philippe Kestemont, Martina Kerscher, Patrick Trevidic, Gerhard Sattler, Simon A. Connolly, Petra Weissenberger, Laura Harrington, and Bernard Biwer
- Subjects
Treatment response ,medicine.medical_specialty ,business.industry ,Dermatology ,General Medicine ,Placebo ,Surgery ,Double blind ,Clinical Practice ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Safety profile ,0302 clinical medicine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Forehead ,Medicine ,Open label ,business ,Adverse effect - Abstract
BACKGROUND In clinical practice, different upper facial areas are commonly treated together. OBJECTIVE To evaluate the efficacy and safety of repeated incobotulinumtoxinA injections for the treatment of upper facial lines (UFL) in a 3-month open-label extension (OLEX) period. MATERIALS AND METHODS In the main study period (randomized, double blind, placebo controlled; n = 156), subjects with moderate-to-severe UFL (glabellar frown lines [GFL], horizontal forehead lines [HFL], and lateral periorbital lines [LPL]) on the 5-point Merz Aesthetics Scales (MAS) received 54 to 64 U incobotulinumtoxinA or placebo. In the OLEX, all subjects (n = 139) received 1 treatment with 54 to 64 U incobotulinumtoxinA. Investigator- and subject-assessed MAS scores were evaluated at rest and maximum contraction. Response was defined either as a MAS score of "none" or "mild" or a ≥1-point improvement in MAS scores. RESULTS A clear, rapid treatment response was seen in each individual treated area and for all areas combined. At Day 30, a response of none or mild at maximum contraction (investigator's rating) was reported for 80.1%, 77.2%, and 66.9% of subjects for GFL, HFL, and LPL, respectively. IncobotulinumtoxinA was well tolerated, with no evidence of an increase in adverse events with repeat injection. CONCLUSION IncobotulinumtoxinA is highly effective for the simultaneous treatment of UFL with a good safety profile (EudraCT Number: 2011-005887-20).
- Published
- 2017
15. Response to 'Facial Line Outcomes (FLO-11) and Facial Line Satisfaction Questionnaire (FLSQ) Meet FDA PRO Guidance'
- Author
-
Martina Kerscher, Benjamin Ascher, Ernst Magnus Noah, Philippe Picaut, Dominique Boineau, Said Hilton, Berthold Rzany, Marc Heckmann, Philippe Le Berre, Magali Volteau, Isaac Bodokh, and Philippe Kestemont
- Subjects
AcademicSubjects/MED00987 ,business.industry ,Applied psychology ,Asj/1 ,General Medicine ,Satisfaction questionnaire ,Personal Satisfaction ,Patient Satisfaction ,Medicine ,Humans ,Surgery ,Patient Reported Outcome Measures ,Line (text file) ,Botulinum Toxins, Type A ,business ,Letters to the Editor - Published
- 2020
16. Effective and Safe Repeated Full-Face Treatments With AbobotulinumtoxinA, Hyaluronic Acid Filler, and Skin Boosting Hyaluronic Acid
- Author
-
Per, Hedén, Doris, Hexsel, Hugues, Cartier, Per, Bergentz, Henry, Delmar, Fernanda, Camozzato, Carolina, Siega, Cecilia, Skoglund, Carolina, Edwartz, Maria, Norberg, and Philippe, Kestemont
- Subjects
Adult ,Male ,Esthetics ,Acetylcholine Release Inhibitors ,Cosmetic Techniques ,Middle Aged ,Skin Aging ,Treatment Outcome ,Patient Satisfaction ,Dermal Fillers ,Face ,Humans ,Rejuvenation ,Drug Therapy, Combination ,Female ,Botulinum Toxins, Type A ,Hyaluronic Acid ,Follow-Up Studies - Abstract
Background: It is important to study full-face aesthetic combination treatments to establish well-founded individual treatment plans. Objective: To evaluate clinical outcome and perception of treatment with either abobotulinumtoxinA (ABO) or hyaluronic acid (HA) filler followed by repeated combined treatment with ABO, HA filler, and Restylane® Skinboosters (RSB). MethodsMaterials: This study was conducted at four sites in Sweden, France, and Brazil and included subjects aged 35-50 years with mild/moderate nasolabial folds and moderate/severe upper facial lines. Monotherapy was ≤125 s.U ABO in at least two upper facial indications with optional touch-up or ≤1 mL HA filler in nasolabial folds/cheeks. At months 6 and 12, both cohorts received ≤125 s.U. ABO in upper facial lines with optional touch-up, ≤2 mL HA filler in nasolabial folds/cheeks (and other facial areas as applicable), and ≤1 mL RSB. Assessments included global facial aesthetic appearance and improvement, first impression, perceived age, wrinkle severity, satisfaction questionnaires, and adverse events. Results: Repeated full-face treatment with ABO, HA filler, and RSB was associated with better aesthetic outcome and higher levels of satisfaction than treatment with ABO or HA filler alone. However, even modest volumes of HA filler achieved good aesthetic outcomes and high satisfaction. Treatment of several indications was well tolerated. Conclusion: Aesthetic improvement and subject satisfaction was high and increased with each treatment. All treatments were well tolerated. These data may be used as support when establishing individual treatment plans. J Drugs Dermatol. 2019;18(7):682-689.
- Published
- 2019
17. Long-term efficacy and safety of abobotulinumtoxinA solution for the treatment of moderate-to-severe glabellar lines: A Phase III, double-blind, placebo-controlled and open-label repeat injection study
- Author
-
Inna Prygova, Catherine Thompson, Benjamin Ascher, Magali Volteau, Philippe Kestemont, Said Hilton, and Bill Andriopoulos
- Subjects
Double blind ,Moderate to severe ,business.industry ,Anesthesia ,Medicine ,Open label ,Toxicology ,Placebo ,business ,Term (time) - Published
- 2021
18. Surgical rejuvenation: Cervico-facial lift technique using the superficial musculoaponeurotic plane technique
- Author
-
José Santini and Philippe Kestemont
- Subjects
Lift (force) ,Orthodontics ,business.industry ,medicine.medical_treatment ,medicine ,Interdental consonant ,Intubation ,business ,Rejuvenation - Abstract
ANESTHESIA AND INSTALLATION The procedure is carried out under general anesthesia in order to avoid heavy inltrations that modify reliefs. The intubation probe should be xed using interdental thread in order for the cheeks to remain free and for the head to rotate. The inltration (adrenalized Xylocaine) is limited to the areas concerned by the cutaneous incision and the strict subcutaneous detachment carried out at the beginning of the procedure (Figure 66.1).
- Published
- 2017
19. Practical anatomy for face-lifts
- Author
-
José Santini and Philippe Kestemont
- Subjects
Computer science ,business.industry ,Face (sociological concept) ,Computer vision ,Artificial intelligence ,business - Published
- 2017
20. Safety and efficacy of incobotulinumtoxinA for the treatment of upper facial lines: A randomized, double-blind, placebo-controlled, phase 3 study with open-label extension
- Author
-
Martina Kerscher, Simon A. Connolly, Philippe Kestemont, Petra Weissenberger, Gerhard Sattler, Patrick Trévidic, Bernard Biwer, and Ernst Magnus Noah
- Subjects
Double blind ,medicine.medical_specialty ,business.industry ,medicine ,Phases of clinical research ,Extension (predicate logic) ,Open label ,Toxicology ,Placebo ,business ,Surgery - Published
- 2018
21. Safety, tolerability, and efficacy of repeat-dose injections of incobotulinumtoxinA In the treatment of upper facial lines: Results from a prospective, open-label, phase 3 study
- Author
-
Ernst Magnus Noah, Bernard Biwer, Martina Kerscher, Gerhard Sattler, Petra Weissenberger, Philippe Kestemont, Simon A. Connolly, and Patrick Trévidic
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,medicine ,Phases of clinical research ,Safety tolerability ,Open label ,Toxicology ,business ,Repeat dose - Published
- 2018
22. Intravenous Hyaluronidase with Urokinase as Treatment for Arterial Hyaluronic Acid Embolism
- Author
-
Philippe Kestemont, Olivier Camuzard, and Rémi Foissac
- Subjects
Urokinase ,business.industry ,Embolism ,Hyaluronoglucosaminidase ,Cosmetic Techniques ,030230 surgery ,Pharmacology ,medicine.disease ,Urokinase-Type Plasminogen Activator ,030207 dermatology & venereal diseases ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,chemistry ,Hyaluronidase ,Hyaluronic acid ,medicine ,Humans ,Surgery ,Hyaluronic Acid ,business ,medicine.drug - Published
- 2016
23. Full-Face Rejuvenation Using a Range of Hyaluronic Acid Fillers: Efficacy, Safety, and Patient Satisfaction over 6 Months
- Author
-
Berthold Rzany, Gerhard Sattler, Nabil Kerrouche, Patrick Trevidic, Y May Ma, Philippe Kestemont, Jean-Charles Dhuin, and Hugues Cartier
- Subjects
Adult ,Male ,medicine.medical_specialty ,Filler (packaging) ,Cosmetic Techniques ,Dermatology ,Dermal Fillers ,Injections ,chemistry.chemical_compound ,Patient satisfaction ,Hyaluronic acid ,medicine ,Humans ,Rejuvenation ,In patient ,Hyaluronic Acid ,Aged ,business.industry ,General Medicine ,Middle Aged ,Surgery ,chemistry ,Multicenter study ,Patient Satisfaction ,Face ,Female ,business - Abstract
Full-face rejuvenation with dermal fillers in patients with multiple aesthetic indications is rarely studied.To assess whether a new range of hyaluronic acid filler is suitable for full-face rejuvenation and to evaluate efficacy, safety, and patient satisfaction.In this 6-month study, participants could receive five different fillers from the same range (HA(E) )for up to eight indications (periorbital lines, tear troughs, cheeks, cheek folds, nasolabial folds, upper lip lines, lips, and marionette lines). Outcomes included global aesthetic improvement, improvement in each indication, adverse events, local tolerability, and satisfaction.Seventy-seven participants with a mean age of 54.5 were enrolled; 48.1% had five or more indications treated. Mean total injection volume (baseline and touch-up) per participant was 6.7 mL. At month 6, 92.1% of participants remained at least improved over baseline, 79.7% of participants were satisfied or very satisfied with the durability of the results, and 63.0% of participants felt a lot or much better than before injection. No specific safety concerns were reported except expected injection site reactions.In participants with multiple indications, full-face rejuvenation using HA(E) provided effective, safe, satisfactory results.
- Published
- 2012
24. Efficacy and safety of a new hyaluronic acid dermal filler in the treatment of severe nasolabial lines - 6-month interim results of a randomized, evaluator-blinded, intra-individual comparison study
- Author
-
Benjamin Ascher, Berthold Rzany, Christiane Bayerl, Michel Poncet, Maurizio Podda, Mohammed Guennoun, Patrick Brun, and Philippe Kestemont
- Subjects
medicine.medical_specialty ,Erythema ,business.industry ,Soft tissue ,Dermatology ,law.invention ,Surgery ,Clinical trial ,Randomized controlled trial ,Tolerability ,law ,Edema ,medicine ,medicine.symptom ,Adverse effect ,business ,Wrinkle - Abstract
Summary Background Hyaluronic acid (HA) fillers are frequently used for the correction of facial soft tissue defects. Aim To compare the efficacy and safety of a novel HA filler, HAE (Emervel Deep), with those of HAP (Restylane Perlane) in the treatment of severe nasolabial folds (NLF). Patients/Methods A split-face, randomized and evaluator-blinded comparison study. Subjects were randomized to receive injection of HAE or HAP on their left or right NLF. Efficacy was evaluated based on the change in Wrinkle Severity Rating Scale (WSRS) from baseline. Local tolerability was assessed based on subject diary during the first 3 weeks after injection. Adverse events were also evaluated. Results At both weeks 12 and 24, the mean improvement in WSRS from baseline was significantly greater for HAE than for HAP (1.58 ± 0.89 vs. 1.33 ± 0.82 at week 24; P = 0.002). Similar volume of both products was injected at baseline and touch-up. Both fillers were well tolerated, with similar worst score distribution and mean score for erythema, edema/swelling, bruising, and pruritus. Significantly less severe pain/tenderness was reported with HAE than with HAP (P
- Published
- 2011
25. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines
- Author
-
Benjamin Zakine, Ali Bougara, Philippe Kestemont, Benjamin Ascher, José Santini, and Martine Baspeyras
- Subjects
Adult ,Male ,medicine.medical_specialty ,Placebo-controlled study ,Facial Muscles ,Dermatology ,Placebo ,complex mixtures ,Drug Administration Schedule ,law.invention ,Patient satisfaction ,Double-Blind Method ,Randomized controlled trial ,law ,Photography ,Humans ,Medicine ,Forehead ,Botulinum Toxins, Type A ,Adverse effect ,Aged ,Intention-to-treat analysis ,business.industry ,Middle Aged ,Skin Aging ,Surgery ,Clinical trial ,Treatment Outcome ,medicine.anatomical_structure ,Patient Satisfaction ,Female ,business - Abstract
Botulinum toxin A (BTX-A) is used to treat glabellar lines but the rigorous demonstration of its efficacy in a well-designed study had never been reported.This study was designed to evaluate the efficacy and the safety of 3 doses of BTX-A in the treatment of glabellar lines.A total of 119 patients with moderate to severe glabellar lines at rest were treated with 25, 50, or 75 U of BTX-A (Dysport, Ipsen) or placebo divided into 5 intramuscular glabellar sites. Outcome measures included evaluations of glabellar lines by independent experts from blinded standardized photographs at rest 1 month after treatment, physician evaluations, and patient assessments during a 6-month period.A significant efficacy was reported for the 3 BTX-A groups for at least 3 months after injection (at least P.015). Investigator and patient evaluations suggested that 50 U was the optimal dose. BTX-A was well tolerated. No blepharoptosis was reported. An evaluation in blinded conditions by independent experts was necessary because the results were overestimated by the investigators.BTX-A is an effective and safe treatment for glabellar lines.
- Published
- 2004
26. Chirurgie plastique esthétique de la face et du cou - Volume 2
- Author
-
Jean-Pierre Bessède, Eric Baggio, Philippe Boudard, Isabelle Catoni, Jean-Baptiste Charrier, Joseph Château, François Disant, Sarah Dufau-Perry, Joëlle Huth, Philippe Kestemont, Justin MICHEL, Thierry Malet, Francesco Perrone, Sylvie Poignonec, Roberto Polselli, Thomas Radulesco, Jean-Marc Ruban, Yves Saban, José Santini, Jean-Marc Thomassin, Florence Turner, Delphine Vertu-Ciolino, Cécile Winter, Jean-Jacques Pessey, Dominique Stoll, Seli ARSLAN, Jean-Pierre Bessède, Eric Baggio, Philippe Boudard, Isabelle Catoni, Jean-Baptiste Charrier, Joseph Château, François Disant, Sarah Dufau-Perry, Joëlle Huth, Philippe Kestemont, Justin MICHEL, Thierry Malet, Francesco Perrone, Sylvie Poignonec, Roberto Polselli, Thomas Radulesco, Jean-Marc Ruban, Yves Saban, José Santini, Jean-Marc Thomassin, Florence Turner, Delphine Vertu-Ciolino, Cécile Winter, Jean-Jacques Pessey, Dominique Stoll, and Seli ARSLAN
- Subjects
- Surgery, Plastic, Face--Surgery, Neck--Surgery
- Abstract
Après la parution de Chirurgie plastique réparatrice de la face et du cou, ce second volume est consacré exclusivement à la chirurgie plastique esthétique. Il apporte un complément indispensable au praticien soucieux d'approfondir ses connaissances. Sont successivement abordés dans ce volume : – la prise en charge du rajeunissement facial et la chirurgie esthétique des paupières ; – les rhinoplasties esthétiques correctrices et fonctionnelles ; – la chirurgie orthognathique de l'adulte et l'esthétique faciale ; – les aspects médicolégaux en chirurgie plastique et esthétique de la face et du cou. Richement illustré, complété de vidéos opératoires en ligne et de nombreux cas cliniques, l'ouvrage, concis et didactique, offre une vision des connaissances pluridisciplinaires indispensables à une prise en charge et une thérapeutique de qualité. Les collaborateurs, praticiens et enseignants, apportent ici toute leur expérience. L'ouvrage s'adresse aux chirurgiens plasticiens, esthétiques, ORL et cervicofaciaux et à tous les spécialistes de chirurgie plastique et esthétique de la face et du cou. Pour accéder au complément en ligne de cet ouvrage, cliquez ici.
- Published
- 2012
27. The Emervel French survey: a prospective real-practice descriptive study of 1,822 patients treated for facial rejuvenation with a new hyaluronic acid filler
- Author
-
David, Farhi, Patrick, Trevidic, Philippe, Kestemont, Dominique, Boineau, Hugues, Cartier, Isaac, Bodokh, Patrick, Brun, Benjamin, Ascher, and Jacques, Savary
- Subjects
Adult ,Aged, 80 and over ,Male ,Adolescent ,Cosmetic Techniques ,Middle Aged ,Injections ,Skin Aging ,Young Adult ,Cross-Linking Reagents ,Cross-Sectional Studies ,Treatment Outcome ,Face ,Humans ,Rejuvenation ,Female ,France ,Prospective Studies ,Hyaluronic Acid ,Aged - Abstract
Emervel consists of a range of 5 hyaluronic acid (HA) fillers (Touch, Classic, Lips, Deep, and Volume), with a fixed HA concentration (20 mg/mL), and various degrees of cross-linking and calibration.To describe the current use of Emervel fillers in France.Prospective multicenter, cross-sectional, real-practice, descriptive survey, including 1,822 patients injected with Emervel fillers for face rejuvenation by 58 French physicians between September 2010 and July 2011. The injection modalities were left to the respective physician's discretion.The physicians were dermatologists (52.3%), surgeons (43.8%), or general practitioners (14.1%). Nasolabial folds (NLF) with a mean severity 2.4 were mainly injected with Emervel Deep (51.0%) and Emervel Classic (36.0%) (mean volume: 1.0 mL), and primarily with the linear retrograde (LR) technique (89.3%). Marionette lines (ML), with a mean severity 2.6 were mainly injected with Emervel Deep (52.5%) and Emervel Classic (34.6%) (mean volume: 0.8 mL), and mainly with the LR technique (79.5%). More than 90% of patients had scores of 0 or 1 for erythema, bruising, edema, and pain. No serious adverse events were reported up to 15 months after the injection.These data could contribute to upcoming international consensus on optimal injection modalities of the Emervel range of HA fillers.
- Published
- 2013
28. Hyaluronic acid fillers on the horizon: roundtable discussion
- Author
-
Gary, Monheit, Philippe, Kestemont, and Hema, Sundaram
- Subjects
Cross-Linking Reagents ,Face ,Humans ,Rejuvenation ,Biocompatible Materials ,Cosmetic Techniques ,Hyaluronic Acid ,Rheology ,Skin Aging - Abstract
In this roundtable discussion, the physicochemical properties and potential clinical applications of two new ranges of hyaluronic acid fillers are reviewed. These fillers display enhanced tissue integration after implantation due to novel manufacturing processes, and one of the ranges is customized for specific clinical applications by variation of filler gel calibration and cross-linking.
- Published
- 2012
29. Sustained efficacy and high patient satisfaction after cheek enhancement with a new hyaluronic acid dermal filler
- Author
-
Philippe, Kestemont, Hugues, Cartier, Patrick, Trevidic, Berthold, Rzany, Gerhard, Sattler, Nabil, Kerrouche, and Jean-Charles, Dhuin
- Subjects
Adult ,Male ,Time Factors ,Cosmetic Techniques ,Middle Aged ,Injections ,Skin Aging ,Cheek ,Imaging, Three-Dimensional ,Patient Satisfaction ,Surveys and Questionnaires ,Humans ,Rejuvenation ,Female ,Hyaluronic Acid ,Aged ,Follow-Up Studies - Abstract
Increasing volume is an important part of facial rejuvenation since volume loss is common and typically age-related. HA E Volume is a moderately firm gel designed to be injected into the subcutaneous tissue for volume enhancement.To assess the efficacy, patient satisfaction, and safety fo HA E Volume in patients with bilateral volume loss of the cheeks.This was a multi-center, six-month, open-label study. Subjects received HA E in the cheeks at baseline, and a touch-up injection was optional three weeks later. Global aesthetic improvement, cheek thickness (caliper measurements),changes in volume using three-dimensional (3-D) photo analysis, adverse events and injection site reactions were evaluated at each visit. Optimal correction was defined as results obtained three weeks after last injection. A subject satisfaction questionnaire was performed three weeks after the last injection.Investigators evaluated the great majority of subjects as much or very much improved in terms of aesthetic improvement of their cheeks at week 3 and at mounts 3 and 6 (89.3%, 90.9%, and 76.4%, respectively). After six months, 65.8 percent of the correction achieved at week 3 (optimal correction) was maintained in terms of cheek thickness (caliper assessments), confirmed by 67.7 percent of the volume maintained based on 3-D volume analyses. The majority of subjects (92.1%) were satisfied or very satisfied with their aesthetic outcome. A good tolerability profile was observed.Treatment with HA E Volume in cheeks led to good aesthetic improvement, sustained results confirmed by caliper and 3-D volume assessments, and high subject satisfaction.
- Published
- 2012
30. Practical anatomy of the face
- Author
-
Antoine Jaklis, José Santini, and Philippe Kestemont
- Subjects
Computer science ,Human–computer interaction ,Face (sociological concept) - Published
- 2008
31. 9. Efficacy and safety of a ready-to-use liquid formulation of abobotulinumtoxinA lyophilisate in moderate to severe glabellar lines: results of a phase 2 randomized, placebo-controlled clinical trial
- Author
-
Annette Stein, Anissa Tse, Philippe Kestemont, Benjamin Ascher, Philippe Picaut, Isaac Bodokh, Berthold Rzany, Markus Dendorfer, Dominique Boineau, Tatjana Pavicic, and Marc Heckmann
- Subjects
Moderate to severe ,Clinical trial ,business.industry ,Anesthesia ,Medicine ,Ready to use ,Toxicology ,business ,Placebo - Published
- 2015
32. Botulinum toxin A in the treatment of glabellar lines: scheduling the next injection
- Author
-
Benjamin Zakine, Thierry Malet, Ali Bougara, José Santini, François Niforos, Benjamin Ascher, Philippe Kestemont, and Martine Baspeyras
- Subjects
medicine.medical_specialty ,business.industry ,Significant difference ,General Medicine ,Time optimal ,Placebo ,Placebo group ,Surgery ,Botulinum toxin a ,Patient satisfaction ,Anesthesia ,medicine ,Intramuscular injection ,Adverse effect ,business - Abstract
Background A single intramuscular treatment with botulinum toxin A (BoNT-A) into the facial muscles underlying glabellar rhytids has been shown to effectively attenuate or totally erase these lines for at least 3 months. Objective We sought to evaluate the optimal time for a second injection of BoNT-A (Dysport, Ipsen). Methods One hundred patients with moderate to severe glabellar rhytids at rest were randomized to a first, double-blind injection of 50 U of BoNT-A (n = 50) divided into 5 intramuscular sites, or placebo (n = 50). At monthly intervals between Month 3 and Month 6, the patient and the investigator consensually decided to repeat the injection with open-label BoNT-A in both groups. The main outcome was the time between the first and second injections. Responder ratings (mild or no glabellar lines) after the first and second injections, patient satisfaction, and safety were also assessed. Results At Months 3 and 4 after the first injection, the cumulative percentage of patients having a second injection was lower in the BoNT-A group compared to the placebo group, with a significant difference at Month 4. Following the first double-blind injection, responder rates were significantly higher in BoNT-A group (up to 75%) compared to placebo up to Month 4, and a large majority of patients were significantly satisfied with the BoNT-A treatment at Month 4 (75% satisfied and completely satisfied versus 9.1% with placebo) and Month 5 (86.7% versus 0%, respectively). Headache was the most frequent adverse event in the BoNT-A group (10% versus 6% in the placebo group). No blepharoptosis was reported. Conclusions The effectiveness of 50 U of BoNT-A was confirmed for the treatment of glabellar lines. A second injection was sought within 3 to 4 months by most patients and investigators. Both injections were safe.
- Published
- 2005
33. Repairing the Loss of Areas of the Palpebromalar Region: A Modified Mustardé Skin Flap Technique
- Author
-
José Santini, Sophie Converset-Viethel, Philippe Kestemont, Nicolas Guevara, and Alexandre Bozec
- Subjects
medicine.medical_specialty ,Cheek ,business.industry ,Skin flap ,Eyelids ,Humans ,Medicine ,Surgery ,Plastic Surgery Procedures ,Surgical Flaps ,business - Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.